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Abstract
Introduction: Thymoquinone (TQ), 2-isopropyl-5-methylbenzo-1, 4-quinone, the main 
active constituent of Nigella sativa (NS) plant, has been proved to be of great 
therapeutic aid in various in vitro and in vivo conditions. Despite the promising 
therapeutic activities of TQ, this molecule is not yet in the clinical trials, restricted by its 
poor biopharmaceutical properties including photo-instability. 
Area covered: This review compiles the different types of polymeric and lipidic 
nanocarriers (NCs), encapsulating TQ for their improved oral bioavailability, and 
augmented in vitro and in vivo efficacy, evidenced on various pathologies. Furthermore, 
we provide a comprehensive overview of TQ in relation to its encapsulation approaches 
advancing the delivery and improving the efficacy of TQ. 
Expert opinion: TQ was first identified in the essential oil of Nigella sativa L. black 
seed. TQ has not been used in formulations because it is a highly hydrophobic drug 
having poor aqueous solubility. To deal with the poor physico-chemical problems 
associated with TQ, various NCs encapsulating TQ have been tried in the past. 
Nevertheless, these NCs could be impending in bringing forth this potential molecule to 
clinical reality. This will also be beneficial for a large research community including 
pharmaceutical & biological sciences and translational researchers. 
Keywords: Nigella sativa; Thymoquinone; nano formulations; bioavailability; polymeric 
nanoparticles; lipid-based formulations
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Article highlights
• Thymoquinone, a strong antioxidant derived from black seed, is a promising 
therapeutic molecule
• Poor biopharmaceutical properties hinder its delivery through conventional methods
• Past research evidenced the usefulness of nano-carrier based strategies to enhance 
its bioavailability and therapeutic efficacy
• This review is focused on the compilation of various researches carried out on 
polymeric and lipidic nanocarriers for the improved delivery of thymoquinone
• Design of nano-carrier based strategies could be beneficial for a large research 
community including pharmaceutical, biological sciences and clinical translational 
researchers.
1. Introduction
Medicinal plants and their phytoconstituents hold a great therapeutic promise for various 
ailments, and thus in the recent times, a noteworthy upsurge in the scientific research 
has been noticed in the area of herbal medicines [1]. Nigella sativa (NS) (also known as 
black cumin seed; family Ranunculaceae) is one of the most promising medicinal plants, 
generally grown in the Mediterranean region and western Asia (India, Pakistan, and 
Afghanistan). The biological activity of NS is attributed to its potential chemical 
constituent i.e., thymoquinone (TQ) (Figure 1). TQ (2-isopropyl-5-methylbenzo-1, 4-
quinone), imparts 30–48% of whole constituents of NS seed oil [2]. It was first isolated 
by El-Dakhakhny in 1963 from NS black seeds using thin-layer chromatography [3]. 
However, it is also found in other plants like Eupatorium ayapana, the leaves of several 
Origanum species, the heartwood essential oils of Calocedrus decurrens, oil of different 
Satureja species, aerial flowering parts of Thymus vulgaris L. and Nepeta distans [4]. 
TQ belongs to the monoterpenoid class of benzoquinone having the molecular formula 
C10H12O2, and corresponding to a molecular weight of 164.20g/mol. It contains a basic 
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quinone ring conjugated to a methyl, and an isopropyl side chain in positions 2 and 5 
respectively [5].
The various therapeutic properties of TQ in in vitro and in vivo models have been 
reported extensively in the literature [6]. Besides, its anti-oxidant [7], anti-inflammatory 
[8], chemo-protective and chemo-curative [9] ability is remarkably good. It can also 
interact with a range of proteins and is competent in inhibiting protein-protein 
interactions [10]. In normal tissues, TQ acts as a robust anti-oxidant, and inhibits the 
production of super xide radicals and lipid peroxidation, or enhance the activities of the 
antioxidant enzymes like superoxide dismutase (SOD), catalase, reduced glutathione 
(GSH), glutathione S-transferase, and quinone reductase [11]. However, in tumors cells, 
TQ induces reactive oxygen species (ROS) generation, and decreases GSH levels in a 
dose-dependent manner [12]. To understand the molecular mechanisms of TQ, 
recognition of its binding targets and identification of distribution profiles inside a 
biologic system can tremendously help [13]. However, in the past, a limited number of 
studies have been reported pertaining to absorption and disposition of TQ. This could 
be attributed to its high hydrophobicity, poor solubility and stability in biological fluids 
[14].
A nanotechnology-based strategy for the effective delivery of thymoquinone could be 
the most promising area for overcoming the aforementioned limitations related to its 
poor biopharmaceutical properties. Encapsulation of TQ in the various nanocarriers 
could improve its in vivo solubility, stability, bioavailability, targeted delivery as well as 
protect it from the unspecific binding [15]. Thus, TQ-Nanoparticles (NPs) are fetching 
more clinically attractive options than pure TQ owing to their enhanced activity in 
modulating disease targets in vitro and in vivo [16,17].
Various researchers have extensively reviewed the therapeutic potential of TQ, mainly 
for its use as an anti-oxidant, anti-inflammatory, and as an anti-cancer agent. However, 
the present review is focused onto give an account on different polymeric and lipidic 
NCs for modulating its biopharmaceutical properties and therapeutic activities.
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2. Challenges in the delivery of TQ
Hydrophobicity and poor aqueous solubility of TQ pose problems in the appropriate 
formulation, and subsequently result in poor systemic bioavailability, and thus might 
require a higher dosing as shown in figure 2. [18]. Besides, TQ is reported to have 
low chemical stability due to its degradation in physiological environments and have 
a high first pass metabolism [19]. Its sensitivity for pH, temperature, and light also 
poses hurdles in the successful formulation development [20,21]. Therefore, the 
clinical transition of this molecule had remained far from reality. In the past, various 
NCs have attempted to overcome the challenges in the delivery associated with this 
molecule.  These NCs based on the biocompatible and biodegradable materials are 
mainly polymers and lipids. The lipidic NCs include liposomes, niosomes, 
proniosomes, SLNs, NLCs, lipospheres, nanoemulsions, and SNEDDS, while, 
polymeric DDS include mainly PLGA, PEG, Chitosan, and cyclodextrin NPs as 
presented in figure 3.
3. Nanocarriers  
3.1. Polymeric NCs
Polymeric nanoparticles have several attributes that make them favorable for drug 
delivery. These include biodegradability, controlled or sustained release, 
biocompatibility with tissues and cells and tunable particle size. They are comparatively 
nontoxic and are stable in blood and lack immunogenicity a d thrombogenicity [13]. 
Polymeric NCs can be useful in targeting the drugs to sensitive regions like brain and 
central nervous system (CNS) as it can cross the blood brain barrier (BBB). These NCs 
are mainly evaluated in cancer and brain targeting. NCs can enhance the bioavailability 
and bioactivity of TQ due to particle size in the nano size range, surface modification, 
and protecting it from the harsh biological environments. The polymeric NCs could also 
modulate the pharmacokinetics and diffusion of TQ into various organs by crossing the 
barriers. A tabular account of various polymeric NCs encapsulating TQ is entailed in the 
Table 1 
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Polymeric nanoparticles can be formulated by several approaches depending on the 
drugs to be encapsulated. Polymeric nanomaterials are drug transporters made of 
natural, synthetic, or semisynthetic polymers in the nanoscale range. Natural polymers 
are the polymers that are produced by living organisms. These highly valuable materials 
can be modified to meet the desired needs of biomedical applications. The natural 
materials employed for TQ-loaded NCs preparation include chitosan, gum rosin, 
alginate etc. Synthetic polymers that are exploited for TQ-loaded NCs construction 
composed of either biodegradable or non-biodegradable polymer backbone, e.g., 
polyvinylchloride, polyethylene glycol (PEG), Poly lactic-co glycolic acid (PLGA), 
polyhydroxyalkanoate (PHA), and cylodextrin (CD). In the current section general 
preparative technology of TQ-loaded NCs employing these aforementioned natural and 
synthetic polymers is explain d. Besides, the research evidences obtained during past 
decades, regarding the usefulness of these NCs for the biopharmaceutical improvement 
of TQ, and targeting to different organs, are also enumerated.
3.1.1 Preparation of NCs
TQ-loaded polymeric NCs were mainly prepared by three methods i.e. 
nanoprecipitation, solvent-evaporation, and ionic gelation method. In the first method, 
the polymer is dissolved in acetone and then dropwise addition into the aqueous phase, 
maintained on a continuous rotation. The organic solvent is then evaporated under 
vacuum. In contrast, the emulsification solvent evaporation method comprises of 
polymers dissolved in volatile organic solvent, which then added into the continuously 
rotating aqueous phase, with or without emulsifier and sonicated. Both methods have 
simple procedures and are appropriate for the encapsulation of lipophilic drugs [22]. The 
key differences between both methods lie in the scale-up and entrapment efficiency. In 
the emulsification solvent-evaporation method, the chances of scaling up is 
comparatively less because it requires high energy in homogenizing and the entrapment 
efficiency is reasonable too. In contrast, the nanoprecipitation method is easily scaled 
up and has high entrapment efficiency, which makes it the most commonly used 
method for the preparation of PLGA nanoparticles [23]. TQ-loaded chitosan NCs are 
mainly prepared by the ionic gelation method, which is a natural linear 
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biopolyaminosaccharide. In this method, nanosized particles are prepared by mixing 
two aqueous phases, one containing chitosan, and the second containing poly-anion 
sodium tripolyphosphate. The positively charged amino group of chitosan interacts with 
negatively charged groups of tripolyphosphate to form coacervates, which subsequently 
leads to the formation of nanosized particles using emulsion cross-linking technique 
[24].
3.1.2 Natural polymer based TQ-loaded NCs
3.1.2.1 TQ-loaded chitosan NCs
Chitosan (CS), a linear copolymer of β-(1,4)-2-acetamido-D-glucose and β-(1,4)-2-
amino-D-glucose, derived from chitin is the most abundant natural polysaccharide after 
cellulose with good biocompatible properties [25]. TQ-loaded CS–NCs have studied in 
the past to target various organs like liver and brain. These CS-NCs are proved to 
enhance the targeting of TQ to the various tissues owing to the cationic nature of the 
CS, and small size, which can extravagate through biological barriers such as the 
blood-brain barrier, and thus enhance the therapeutic effectiveness of the encapsulated 
drug [26].
Alam et al. determined the biodistribution and pharmacokinetics of TQ-loaded CS NCs 
via. nose-to-brain targeting [19]. The NCs formulated by ionic gelation method, and 
characterized for particle size by dynamic light scattering, morphology by TEM and 
SEM, in vitro kinetics and ex vivo release, and X-ray diffractometry (XRD) studies, for 
investigation of the physical form of the drug inside the NC. Findings suggested the 
smaller particle size (200 nm) with good entrapment efficiency (63.3%). TQ-NC were 
spherical in shape, amorphous nature, revealed sustained release pattern and 
enhanced drug permeation. Furthermore, pharmacokinetics studies revealed 
approximately 15-fold enhancement in brain targeting efficiency of TQ-CS-NCs in 
comparison to the TQ solution. This might be due to the cationic TQ-CS systems, which 
showed higher targeting efficiency due to the interaction of a positively charged amino 
groups present on the carbon two position of CS, with negatively charged groups on the 
cell membranes. Similarly, other possible mechanisms could be its ability to cross the 
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tight junctions of the mucosal epithelial cells. Moreover, smaller particle size of NCs and 
lipophilic nature of TQ might have resulted in the enhanced partitioning across the BBB. 
In another study, Zafar et al. prepared CS-grafted lipid nanocapsules for the co-delivery 
of docetaxel (DTX) and TQ in the drug-resistant breast cancer cells, i.e., MCF-7 and 
triple-negative MDA-MB-231 cells [27]. These nanocapsules prepared employing high-
speed homogenization and ultrasonication methods and optimized employing 33-Box-
Behnken design to get the desired quality attributes. Endosome escape study was also 
performed for the selective and efficient delivery of drug in the tumor site. Results 
revealed that the optimized nanocapsules exhibited high drug loading of both the 
encapsulated drugs DTX and TQ, uniform particle size (< 200 nm), and controlled drug 
release. The CS being a cationic polymers showed pH buffering properties and thus 
facilitated the delivery of TQ into the cytosol, improved cellular uptake aided in the 
endosomal escape effect, and led to a significantly higher cytotoxicity against MCF-7 
and triple-negative (MDA-MB-231) breast cancer cells. The enhanced effect of these 
CS nanocapsules might be due to the protonation, which leads to the extensive influx of 
ions and water into the endosomal sections, initiating the disruption of the endosomal 
membrane, thus delivering the entrapped TQ. 
Recently, Othman et al. were able to demonstrate that CS NCs could encapsulate one 
hydrophobic (TQ) and other hydrophilic (L-ascorbic acid) drug together, employing ionic 
gelation method [28]. Results showed that NPs were found to be in the nanosized 
range, spherical and had good encapsulation efficiency for both the encapsulated 
drugs. In one study, Aljoufi et al. prepared and evaluated TQ-loaded CS lipidic NCs for 
the effective treatment of the liver disorder. TQ-loaded CS vesicle were prepared 
employing solvent evaporation and probe sonication method [29]. The developed NCs 
were then characterized for vesicle size, entrapment efficiency, morphology, in vitro 
drug release, ex vivo drug permeability, mucoadhesive properties and anti-
hyperlipidemic activity. Results showed that the prepared NCs showed nano size range 
(372.8 nm), low PDI (0.175), high encapsulation efficiency (82.23%), optimum drug 
release profile, significantly higher flux (1.9 fold) and mucoadhesive property (4.4 fold) 
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vis-à-vis free TQ. Findings from anti-hyperlipidemic activity showed the significant 
changes in biochemical parameters (SGOT, SGPT, and ALP) and lipid profile (TC, LDL, 
HDL), which was further confirmed by histopathological evaluation. Histopathology of 
liver treated with toxic control revealed the inflammatory cells, swelling of hepatocytes 
and occurrence of hepatitis whereas TQ-loaded NCs treated groups showed minimal 
central vein inflammation. These lipidic NCs coated with chitosan prolong the circulation 
time, modify the release behavior, drug targeting, improve the drug permeability and 
enhance drug stability. These NCs can also prevent the absorption of plasma protein by 
providing a hydrophilic steric stabilization to the surface of lipid vesicle and thus, 
improve the absorption of TQ by efficiently crossing the barriers.
3.1.2.2 Gum-rosin-loaded polymeric nanocapsules 
Nanocapsules are the typical class of polymeric NCs, composed of one or more active 
drug substance (core) and a protective matrix (shell) made up of polymeric or lipidic 
membrane, in which the active constituents may be encapsulated. Nanocapsules have 
attracted tremendous interest as they can be utilized for the controlled and targeted 
release of drugs contrary to the protection of enzymes, proteins, and foreign cells 
[30,31].
Rani et al. formulated two different nanoformulation (NFs), one is glycyrrhizin (GL) 
loaded nanocapsule prepared via ionic gelation method and other is TQ-loaded gum 
rosin nanocapsule prepared employing nanoprecipitation method. Both NFs in 
combination or separately were studied for anti-hyperglycemic potential in 
streptozotocin-nicotinamide induced type-2 diabetes rat model [32]. The prepared NFs 
were characterized for particle size, stability, morphology, and in vivo behavior. TQ-
loaded NCs were found to be stable, spherical in shape with nanometric size range (100 
nm) and sustained release behavior as compared to their pure forms. Results from in 
vivo studied endorsed that combined NFs were significantly able to decrease blood 
glucose level, glycate haemoglobin and improve the lipid profile of diabetic rats as 
compared to metformin in a dose-dependent manner. This enhanced anti-diabetic effect 
of NFs might be due to improvement in its bioavailability and increase drug 
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concentration in the blood, owing to the advantage of nanoscale therapeutics. 
Additionally, improved anti-diabetic action is the synergistic effect of two NFs, which 
ultimately improved pharmacological activity.
3.1.3 Synthetic polymer based TQ-loaded NCs
3.1.3.1 TQ-loaded PLGA NCs
PLGA is one of the most abundantly used polymers for the preparation of 
nanomedicine, which has also been approved by the US-FDA. It has minimal systemic 
toxicity as it gets hydrolyzed in the body to biodegradable lactic acid and glycolic acids, 
which are metabolized in the body via the Krebs cycle and removed as carbon dioxide 
and water [33]. Past studies report that PLGA is a non-toxic polymer grounded on cell 
culture and animal experiments [34,35]. TQ-loaded PLGA NCs were used to target 
different types of cancer and for their anti-microbial potential.
Nallamuthu et al. determined the anti-oxidant and anti-bacterial potential of TQ-loaded 
PLGA NCs [36]. TQ-loaded PLGA NCs were prepared by solvent evaporation method 
and characterised  for  particle  size,  morphology, entrapment efficiency, in vitro 
release, antioxidant  and anti-microbial activity. The in vitro anti-oxidant ability of 
encapsulated TQ was assessed employing DPPH radical scavenging assay.  Whereas, 
anti-bacterial property were tested by modified agar-well diffusion method against E. 
coli, Staphylococcus aureus, and Salmonella typhi strains. Results from particle  size 
and SEM studies revealed the mean particle size of < 200 nm and %EE of about 62%. 
However, in vitro drug release study showed sustain release of TQ at 75% and 54 % 
respectively for artificial intestinal and gastric juices over the period of 7 days and DPPH 
radical scavenging activity of the TQ-NCs was found to be 71% at 1 mg/mL 
concentration. The results showed that PLGA encapsulated TQ–NPs were able to offer 
sustained release property and enhanced antioxidant as well as anti-microbial activity 
vis-a-vis  pure TQ [37].
In other study, Ganea et al. evaluated the anti-cancer potential of TQ using molecular 
micelle modified PLGA NCs for breast cancer [38]. The NCs were synthesized 
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employing emulsification solvent evaporation method, using the molecular micelle poly 
(sodium N-undecenyl-glycinate) (poly-SUG) as an emulsifier and optimized employing 
Box-Behnken experimental design. TQ-loaded NCs were evaluated for particle size and 
%EE. The cytotoxic effect of TQ and TQ-loaded PLGA NCs were assessed using MDA-
MB231 breast carcinoma cells. Findings showed that molecular micelles provided 
maximum optimized TQ entrapment efficiency, and uniform particle sizes (200 nm). TQ-
loaded PLGA NCs showed approximately five-fold enhancement in cell viability than 
blank NCs and non-treated cells, and effectively able to inhibit the growth of breast 
carcinoma cells vis-à-vis free TQ [39]. In breast cancer cells, TQ interfered with 
PI3K/Akt signaling, and stimulated G(1) arrest, and thus induced cell apoptosis. 
Moreover, TQ inhibited p53-mutated acute lymphoblastic leukemia cells by the 
activation of a p73-dependent mitochondrial cell [40,41]. However, enhanced anti-
cancer effect of NCs might be due to the interactions between cells and NCs, which 
leads to the accumulation of NCs in the cells, and thus release the TQ in the 
extracellular and intracellular spaces. 
Similarly, Abdel-Mottaleb et al. evaluated anti-cancer potential of TQ-NCs employing 
different polymers viz. PLGA, ethylcellulose (EC) and polycaprolactone (PCL) for 
colorectal cancer employing murine mouse model [42]. Solvent evaporation technique 
was employed for the fabrication of NCs. Prepared NCs were then characterized for 
particle size, PDI, entrapment efficiency, surface morphology, in vitro release and in 
vivo studies. Results showed that the particle sizes were in the nano range with all the 
polymers used, but TQ-PCL-NCs showed maximum uniformity in size and stability. 
Further, particles were spherical in shape with smooth surface texture. In vitro drug 
release showed burst release of 50% TQ in the first hour followed by sustain drug 
release. Findings obtained from in vivo studies were similar to Ganea and co-authors, 
suggesting the superiority of TQ-NCs as compared to the pure TQ, in terms of tumor 
growth retardation and animal survival. TQ acts as a potent inhibitor of the NF- κB 
pathway and reduces tumor angiogenesis [43-46]. Besides, TQ bindings to oncogene 
PAK1, thus changes its conformation and scaffold function, which further interferes with 
RAF/MEK/ ERK1/2 pathway and controls cancer cell growth [47]. Furthermore, authors 
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suggested that TQ encapsulation into polymeric NCs could enhance its uptake by the 
cancer cells especially with the leaky vasculature along with poor lymphatic drainage 
into tumors, which is also known as the enhanced permeation and retention effect 
(EPR). 
Similarly, Verma et al. also determined the anti-cancer potential of Topotecan-TQ-
loaded PLGA NCs employing MTT assay in HEK293 cell lines [48]. Topotecan-TQ-
loaded PLGA NCs were formulated employing modified double emulsion solvent 
evaporation method and optimized using central composite design (CCD). These NCs 
were then characterized in terms of zeta potential, surface morphology, DSC, XRD and 
drug release. Optimized formulation showed nano-range particle size (240.7±8.3 nm) 
with uniform size distribution, good percent entrapment, and loading efficiency (62.6±2.6 
and 6.52±0.25) for thymoquinone and for topotecan (42.3±1.2% and 3.6±0.26) 
respectively. DSC and XRD studies revealed the conversion of drug from its crystalline 
to amorphous form when entrapped inside the PLGA NCs. Findings were in agreement 
with previously reported studies suggesting the maximal activity of TQ co-encapsulated 
PLGA NCs, while offering exposure to tumor cells for a prolonged period of time vis-à-
vis pure TQ.  Authors proposed that co-encapsulation of topotecan and TQ could be an 
effective therapy for the treatment of solid tumors. While topotecan is a well 
acknowledged and broadly used drug for the treatment of various cancers, approved by 
the FDA, TQ has been extensively explored over fifty years in various carcinomas [49].
3.1.3.2 TQ-loaded PEG NCs
Polyethylene glycol (PEG) is a water-soluble, non-toxic, non-immunogenic and FDA-
approved polymer [50]. PEG restricts the passage through the blood-brain barrier thus 
abolishing neurotoxicity linked with free drug or phytochemical and prolongs the 
circulating half-life of the free drugs or phytochemicals. PEG has been used as a 
polymer for the encapsulation of several drugs viz. doxorubicin [51] and paclitaxel [52] 
for treatment of cancer. Anti-cancer potential of TQ-loaded PEG NCs were also studied 
in the past. This polymer is self-assembled into amphiphilic NCs having a hydrophobic 
core and hydrophilic shell. 
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Shah et al. determined the neuroprotective effect of amphiphilic polyhydroxyalkanoate 
(PHA) monomethoxy polyethylene glycol (mPEG) co-polymeric nano-containers [16]. 
Co-polymer were synthesized via. chemical coupling of poly (3-hydroxybutyrate-co-3-
hydroxyvalerate), P(3HB-co-3HV) or poly(3-hydroxybutyrate-co-4-hydroxybutyrate), 
P(3HB-co-4HB) to mono-methoxy poly(ethylene glycol) (mPEG) through trans-
esterification reaction. Findings suggested that the encapsulation of TQ into NPs 
showed the extended release for TQ compared to pure TQ. 
Anti-cancer potential of TQ-loaded PEG4000-NCs was studied by Bhattacharya et al. 
via deregulation of cytoskeletal actin polymerization through miR-34a [17]. TQ-loaded 
PEG4000-NCs were formulated employing nanoprecipitation method and characterized 
for particle size and surface morphology. Particle sizes of TQ-PEG4000-NCs were 
found to be less than 50 nm and nearly spherical morphology with smooth surface 
texture. Results validated that PEG4000-TQ-NCs significantly augmented the 
expression of miR-34a through p53. NCs also mediated miR-34a up-regulation, directly 
downregulated Rac1 expression, monitored by actin depolymerization, thereby 
disrupting the actin cytoskeleton, which significantly retards the cell migration. In 
addition, authors evidenced that PEG4000-TQ-NCs exhibited strong specificity to 
cancer cell migration, showing less toxicity towards the normal cells in comparison to 
that of TQ alone at a significantly lesser dose than pure TQ.
3.1.3.3 TQ-loaded CD NCs
CD are the family of cyclic oligosaccharides generally including 6–8 d-glucose units, 
forming inclusion complexes with altered molecules in aqueous solution and in the solid 
state [53]. CD have been used as complexing agents in many pharmaceutical 
preparations to improve the solubility, bioavailability, safety and stability of different 
drugs including anti-cancer drugs [54]. TQ-loaded CD-NCs were prepared to evaluate 
the anti-cancer potential of TQ.
Abu-Dahad et al. evaluated the anti-proliferative potential of TQ-β-CD self-assembling 
NCs [55]. These NCs were characterized for particle size, zeta potential, morphology, 
DSC and FT-IR. Findings suggested that average particle size was found to be 
445±100nm with a charge 21.8mV and nearly spherical morphology. Further, the safety 
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was estimated via. cell viability studies employing normal periodontal fibroblasts and 
anti-proliferative activity by means of the adenocarcinoma cell lines (MCF-7). A very 
less IC50 value (4.70±0.60 microM) for TQ-CD NCs vis-à-vis free TQ solution (24.09 
±2.35 microM) was observed after 72 h of incubation, which means TQ-CD NCs had 
higher anti-proliferative effects in comparison to free TQ. This enhanced anti-
proliferative potential of TQ-CD-NCs, is mainly due to improved cellular permeation. In 
addition, TQ-CD NCs were found to be less toxic against human periodontal fibroblasts 
vis-à-vis free TQ. Previous reports suggested that TQ could induce apoptosis in MCF-7 
breast cancer cells via the up-regulation of p53 expression. Besides, TQ significantly 
increased the expression of miR-34a via p53, and down-regulated Rac1, led to actin 
depolymerization, and interruption of the actin cytoskeleton. This damage in the actin 
cytoskeleton hampered the c ll migration [47].
3.1.3.4 Silica NCs
In recent study Khattabi et al. studied the in vitro cell toxicity of prepared thymoquinone-
melatonin (TQ-MLT) silica NP’s towards HeLa cells [56]. Findings suggested that longer 
polymers showed a more sustained release in a pulsatile manner. The in vitro cell 
viability assay also exhibited that the percentag  of cell toxicity to HeLa cells increased 
with increasing the polymer length. In HeLa cell lines, TQ were found to down-regulate 
the androgen receptor (AR) and regulate E2F-1 cell proliferation.
3.1.4 Hybrid NCs
Hybrid NCs comprise organic–inorganic, lipidic, polymeric, and natural 
macromolecule/synthetic polymer based NCs. Hybrid NCs can be prepared via 
encapsulation and grafting of inorganic components or natural macromolecules by 
(co)polymerization, precipitation of polymers in the presence of inorganic constituents 
by solvent displacement techniques [57]. These hybrid NCs exploit the benefits of both 
systems (lipid and polymer/organic and inorganic materials) in terms of different 
characterization parameters [58]. 
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3.1.4.1 TQ-loaded PLGA-CS NCs
Xiaxo et al. prepared TQ-loaded PLGA-CS NCs by emulsion solvent evaporation 
method and characterized for particle size and zeta potential [59]. Findings suggested 
that TQ-loaded PLGA-CS NCs showed particle size in nano range (183.5±8.2 nm) with 
positive zeta potential, (33.63±2.25mV). These NCs were evaluated for neuroprotective 
efficacy and delivered via nose to brain route in the rodent cerebral ischemia-
reperfusion model. The pharmacokinetics of TQ-loaded PLGA-CS NCs were also 
studied in the brain and blood plasma along with localization studies of florescent 
labelled PLGA-chitosan NCs in brain tissues. Authors showed that the pharmacokinetic 
and localization studies facilitated the delivery of TQ to brain by intranasal nose to brain 
transport pathways. The authors found approximately 28-fold enhancement in systemic 
bioavailability. Authors mentioned that this enhanced intranasal effect was due to 
improved paracellular transport through epithelial tight junctions via. interaction with the 
protein kinase C pathway or electrostatic interaction with negative charged sialic acid 
residues on mucosal epithelial cells.
3.1.4.2 TQ-loaded PEG modified CS Nanocapsules
Kumar et al. evaluated the TQ-loaded PEG modified CS NCs for anti-cancer potential 
employing MCF-7 cell lines and HEK 293 human embryonic kidney cell lines. TQ-
loaded PEG modified CS NCs were prepared via. ionic gelation method [60]. 
Optimization of prepared NCs was done based on particle size, surface morphology, 
PDI, entrapment efficiency, % yield, in vitro release, FT-IR and X-RD studies etc. 
Findings from in vitro drug release studies revealed that TQ-loaded PEG modified CS 
NCs showed slow and sustained release vis-a-vis pure TQ, whereas 100% inhibition of 
breast cancer cells was observed in 50 mg/mL and 100 mg/mL concentration at 48 h of 
incubation. Authors suggested that CS readily solubilized in the intracellular and 
intercellular acidic environment of tumor cells owing to its pKa value (6–6.5), which then 
release TQ directly in the cancer site and thus prolonged bioavailability in the 
intracellular environment.
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3.1.4.3 TQ-loaded PLGA-PEG-loaded NCs 
Admad et al. studied the cytotoxic effects of TQ-PLGA-PEG NCs in Tamoxifen-resistant 
breast cancer cells [61]. Cytotoxicity studies performed employing MTT assay exhibited 
enhanced IC50 of TQ-NCs at 20.05 μM and free TQ was 8.25 μM respectively. Findings 
suggested that the bioavailability of drug found to preserve within NCs compared to free 
TQ and act gradually on target cells. 
3.2. Lipidic NCs
As stated earlier, the major challenge in TQ-loaded formulations is their low aqueous 
solubility. Lipid-based delivery systems, therefore, provides a noble approach, to 
improve the bioavailability and stability of sensitive materials amid numerous 
advantages in drug delivery. Furthermore, the formulation in a lipid matrix system can 
sustain the drug release, thus contributing to a decrease in the peak drug 
concentrations in systemic circulation and probably, to avoid side effects attributed to 
oral delivery. The drug-loaded lipidic NCs can also use to target the particular disease in 
a specific organ. Lipidic NCs systems are classified mainly into two categories, i.e., 
particulate type and non-particulate types. Particulate type systems solid lipid 
nanoparticles (SLNs), nanostructured lipid carri rs (NLCs), dendrimers, nanogels, 
microparticles, microsphere, liposomes, niosomes, proniosomes etc. Whereas, non-
particulate type carrier-systems include microemulsions, nanoemulsion, and self-
nanoemulsifying drug delivery systems (SNEDDS), etc. A tabular account of various 
lipidic NCs encapsulating TQ is entailed in the Table 2 
3.2.1 Preparation of TQ loaded lipidic NCs
TQ-loaded lipidic NCs were mainly prepared by four methods i.e. solvent-injection, 
microemulsification method, high-speed homogenization, and nanoprecipitation method.  
Among these methods, solvent injection method is the simplest one. In this method lipid 
first dissolved in water miscible organic solvent (ethanol, acetone, isopropanol). This 
solution then injected through a syringe needle in water under stirring. Lipid is 
precipitated as nanoparticles when encounters water. In microemulsification method, 
drug dissolved in organic solvent (ethanol, acetone, isopropanol). The lipids are heated 
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above their melting point (lipid phase), whereas surfactants and co-surfactants are 
dissolved/dispersed in a portion of water (aqueous phase). Then all the phases i.e., lipid 
phase, aqueous phase and the drug solution mixed isothermally to form a clear 
microemulsion. The clear microemulsion so formed then added into ice-cold water at 
4°C and continuously stir at 3000 rpm for about 20 min to fetch the nanoparticles. In 
high-speed homogenization, the polymer and drug heated, melted, and then dispersed, 
in the aqueous phase containing lipid by continuous mixing, to obtain an emulsion.  
Emulsion then subjected to high pressure, high-speed impact, and decompression 
expansion, after which high shear forces steadily break down the fluid droplets to the 
desired nanoparticle size range. In nanoprecipitation method, polymers and drugs first 
dispersed in water miscible solvents (e.g., acetone and acetonitrile). Then, the resulting 
solution added drop wise into a lipid-containing aqueous phase, and the mixed by 
spinning and homogenization to obtain nanoparticles [62].
3.2.2 Particulate type NCs
3.2.2.1 TQ-loaded NLCs
NLCs are novel colloidal lipid-based systems that create a hybrid blend of incompatible 
solid and liquid lipids. TQ-loaded NLCs resulted in enhanced pharmacokinetic, 
bioavailability, controlled drug release and ultimately improved drug absorption by 
protecting the drug from extensive first-pass metabolism, P-gp efflux of the drug 
transporters, and intra-enterocyte metabolism. These characteristics of NLCs are mainly 
attributed to their unique composition, which is constituted of a blend of incompatible 
solid and liquid lipids [63]. TQ-loaded NLCs were used to target liver and cancer cells. 
Abdelwahab et al. reported the gastro-protective activity of TQ-NLCs against ethanol-
induced ulcers in rats and pharmacokinetic profile was evaluated in the rabbits [64]. TQ-
loaded NLCs were evaluated for particle size, zeta potential and in vitro toxicity. 
Findings suggested that the particles size was in nano-range (75 ± 2.4 nm) with 
negative zeta potential values of −31 ± 0.1 mV. Findings from the in vivo study 
suggested that TQ-NLCs suppressed the formation of ethanol-induced ulcers via the 
modulation of heat shock protein-70 (Hsp70). Moreover, extravascular administration of 
TQ-NLCs showed enhanced pharmacokinetic profile viz. increased bioavailability and 
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sustained concentrations in blood. Similarly, Elmowafy et al. evaluated the TQ-loaded 
NLCs for oral bioavailability and hepato-protective activity compared to pure TQ [65]. 
TQ-loaded NLCs were prepared by high-speed homogenization followed by 
ultrasonication and evaluated for particle size, polydispersity index, zeta potential and in 
vitro studies. Hepato-protective potential of TQ-NLCs were evaluated employing 
biochemical parameters and histopathological evaluation. Optimized TQ-NLC 
formulation showed smaller particle size (141.9±5.1), smaller PDI (0.2), and negative 
zeta potential values (−58.6±0.5 mV) with high encapsulation efficiency (96.2±1.6%). 
Pharmacokinetic results revealed that there was approximately 3-fold enhancement in 
relative bioavailability. Enhanced hepato-protective potential of TQ-NLCs was observed 
vis-à-vis TQ suspension based on biochemical parameters. This enhanced effect could 
be due to stabilization of the membranes, which then prevents the leakage of 
intracellular enzymes. Further, owing to the anti-oxidant potential, TQ exhibited a 
decline in malondialdehyde and elevation of reduced glutathione levels. 
Keat et al. studied the anti-cancer potential of TQ-NLCs on breast cancer cell lines 
(MCF-7 and MDA-MB-231) and cervical cancer cell lines (HeLa and SiHa) [66]. TQ-
NLCs prepared employing high-pressure homogenization and then characterized for 
various physicochemical parameters and stability. Findings suggested that the mean 
particle size of TQ-NLC was in nano range (35.66 ± 0.1235 nm) with a narrow 
polydispersity index (PDI) (0.25) and negative zeta potential (−30 mV). 
Pharmacodynamic studies showed that TQ-NLCs exhibited enhanced anti-proliferative 
activity against all the cell lines in a dose-dependent manner vis-à-vis pure TQ. TQ 
induced apoptosis and non-phase specific cell cycle arrest in MDA-MB-231 cells, 
suggesting it to be a potentially effective chemotherapeutic agent against hormonal 
independent breast cancer.
Recently, Rathore et al., studied the hepato-protective potential of TQ in the form of 
phospholipidic nanoconstructs (PNCs) employing Paracetamol-induced hepato-toxicity 
animal model [67]. PNCs were constructed employing microemulsification technique 
and optimized by three-factor three level Box-Behnken design. Results showed that 
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optimized PNC composition exhibited nano size (<100 nm), spherical morphology, 
within acceptable range of polydispersity index (0.55), high drug entrapment efficiency 
(>90%), controlled drug release pattern, and neutral surface charge (zeta potential of 
−0.65 mV). TQ-PNC showed approx. 3.9-fold enhancement in the relative bioavailability 
vis-à-vis TQ-suspension. Pharmacodynamic data showed a significant decrease in the 
serum biomarker enzymes in PNCs treated group vis-a-vis control and marketed 
(SILYBON®) formulations against paracetamol (PCM)-induced liver cirrhosis. This 
enhanced effect might be due to the higher cellular permeability of TQ achieved by 
PNCs. PNCs, and are anticipated to interact with the membrane lipids of liver cells 
resulting in physiologically significant effects. Moreover, the presence of lipidic carrier 
facilitates capture by the liver and other organs 
3.2.2.2 TQ-loaded SLNs
SLNs was introduced in the early 90s and are categorized by the presence of a mixture 
of one or more solid lipids responsible for controlled drug release. Solid lipid 
nanoparticles (SLNs) are novel colloidal drug delivery system, formulated to protect the 
drug from chemical degradation to attain controlled drug release ability, good 
tolerability, biodegradability, physical stability and efficient encapsulation of lipophilic 
drugs in their lipid structure [68]. TQ-loaded SLNs can be formulated to target various 
organs like liver and brain and for bioavailability enhancement [69]. SLNs have potential 
to be used as alternative drug delivery system for many lipophilic molecules.
Pathan et al. developed a rapid, sensitive and selective UPLC method to estimate TQ in 
pure form and in NCs formulation (TQ-SLNs) [12]. TQ successfully quantified in TQ-
SLNs formulation employing in vitro as well as oral in vivo pharmacokinetic study. 
Findings suggested the 2-fold enhancement in the relative bioavailability of TQ-SLNs in 
the rat’s plasma, when administered orally vis-à-vis pure drug. Similarly, in other study 
Singh et al., prepared and evaluated TQ-SLN for modulation in the pharmacokinetics 
and its hepato-protective activity [70]. TQ-SLNs were prepared by solvent injection 
method and optimized using BBD. Findings showed that optimized TQ-SLNs were of 
desired characteristics in terms of particle size (166.1±10.96 nm), entrapment efficiency 
Page 20 of 69





























































For Peer Review Only
Information Classification: General
(71.60±3.85%) and high drug release (70.95±2.47%). In pharmacokinetic study, authors 
found nearly 5-fold enhancement in the bioavailability of TQ-SLN compared to pure TQ 
suspension. Findings from pharmacodynamic data exhibited a significant decrease in 
the serum biomarker enzymes in TQ-SLNs treated group vis-a-vis control and marketed 
(SILYBON®) formulations against paracetamol (PCM)-induced liver cirrhosis. It could 
be due to the passage of TQ-SLNs via the endothelial fenestrations, where the hepatic 
stellate cells (HSCs) are present. A direct inhibition of the activated HSCs by TQ might 
be the reason of improved hepatoprotective activity of TQ-SLN. In other findings, TQ-
loaded SLNs studied for their brain targeting ability [71]. The SLNs prepared by 
microemulsifcation method and evaluated for 3-nitroproponic acid induced Huntington's 
disease-like symptoms in Wistar rats, pharmacokinetics and bio-distribution analysis. 
Pharmacokinetic results were similar to Singh et al. as they also found nearly 5-fold 
enhancement in oral bioavailability of TQ vis-à-vis pure TQ. Further, the drug 
distribution analysis showed that TQ-SLNs was found to accumulate more in the brain 
than other organs, hence suitable for the brain targeted drug delivery. Authors asserted 
that TQ-SLNs comprised of lecithin, a choline containing phospholipid might have 
resulted in the acetylcholine synthesis and helped in the reduction of various behavioral 
disturbances in 3-NP intoxicated animals. Moreover, TQ being an anti-oxidant moiety, 
significantly reduced the endogenous protein carbonyls and lipid peroxidation. Similarly, 
the same group have also assessed the potential of TQ-loaded SLNs in 
neuroinflammation and motor abnormalities via 3-NP induced Huntington’s disease [72]. 
Findings were similar to the previously reported findings suggesting TQ-SLNs treatment 
significantly eradicates the nuclear translocation of p-p65 NF-kB and levels of pro-
inflammatory markers viz. TNF-α, IL-1β, IL-6, iNOS, COX-2. The beneficial effect of TQ-
SLNs might be endorsed by the anti-inflammatory potency of TQ. 
Recently, our lab has reported TQ-loaded phospholipid NCs (PLNs) prepared via micro-
emulsification technique employing different phospholipid concentrations, and 
extensively characterized for particle size, surface charge, surface morphology, 
entrapment efficiency, and drug release kinetics [8]. Furthermore, these NCs were 
evaluated for oral bioavailability and anti-inflammatory potential employing rat paw 
edema model. Results showed that particle size was found to be in nanosized range 
Page 21 of 69





























































For Peer Review Only
Information Classification: General
(100nm), higher drug entrapment efficiency (> 70%), controlled drug release pattern 
(Higuchi release), and negatively charged surface (zeta potential of −0.57 mV). After 
oral administration of single dose of TQ-PLNs approximately 2.3-fold enhancement in 
relative bioavailability was observed vis-à-vis plain TQ suspension. Findings from 
pharmacodynamic study showed significantly higher reduction in the percent paw 
inhibition in case of TQ-PLNs (84.27± 2.93%) vis-à-vis pure drug suspension (81.10± 
4.79%) and diclofenac sodium (83.01± 2.63%) respectively. The improved oral 
bioavailability of the drug from lipidic matrix was probably because of the nano-sized 
lipidic PLNs. Furthermore, absorption of PLNs through intestinal lymphatic uptake 
directly transport the drug to the systemic circulation, thus bypassing the liver and 
resulting in enhanced oral bioavailability vis-a-vis pain TQ. Whereas, the enhanced anti-
inflammatory potential of PLN formulation attributed to the encapsulation of drug in 
lipidic matrix, which subsequently resulted in the slow drug release, for prolonged period 
of time, vis-à-vis plain TQ, and marketed formulation.
3.2.2.3 TQ-loaded Niosomes 
Niosomes are non-ionic surfactant vesicles, have a special role in improving poor 
bioavailability, stability and acts as a solubilizing matrix, and a local depot for sustained 
release These are spherical lipid bilayers capable of entrapping water-soluble 
molecules within an aqueous domain or alternatively lipid molecules within lipid bilayers 
[73]. They may be unilamellar or multilamellar depending upon the method used for 
their preparation TQ was encapsulated inside niosomes to target the cancer. 
Rajput et al. evaluated the anti-cancer potential of TQ-loaded multilamellar Gold 
niosomes (Nio-Au-TQ) and small interfering RNA (siRNA) [74]. siRNA-based targeted 
delivery holds potential as a tumor-selective gene silencing approach in cancer therapy. 
The prepared niosomes were tested in vitro against tamoxifen-resistant (MCF-7/Tam 
and T-47D/TAM) and Akt-overexpressing (MCF-7/ Akt) cells and in vivo in a BALB/c 
(nu+/nu+) mouse xenograft model of MCF-7/TAM. Results revealed the concentration-
dependent decrease in cell growth and viability for TQ, Nio-Au-TQ, and siRNA-Nio-Au-
TQ. Further, result showed that siRNA-Nio-Au-TQ is much higher cytotoxic than TQ and 
Page 22 of 69





























































For Peer Review Only
Information Classification: General
Nio-Au-TQ in resistant breast cancer cells, which might be elucidated via. sustained 
siRNA and drug release. In addition, in vivo findings suggested that Nio-Au-TQ and 
siRNA-Nio-Au-TQ showed significantly higher inhibition of tumor proliferation and 
apoptosis than pure TQ. Authors elucidated that net positive charge present in 
niosomes enables its binding to negatively charged cell membranes followed by 
internalization via endocytosis. Endosomal escape caused due to cationic gold in the 
niosomes, which induces endosomal swelling and hence rupture. During endosomal 
rupture, the influx of protons creates an acidic environment that stimulates the 
dissolution of the ni somes inside the cytosol and thus maintain the therapeutic drug 
concentrations deep inside the tumor tissues. 
 
3.2.2.4 TQ-loaded proniosomes
Proniosomes are the latest approach in the family of vesicular systems. It is the pro-
vesicular approach to niosomes, which are converted to niosomes upon hydration [75]. 
It escapes many problems related to aqueous niosome dispersion viz. aggregation, 
fusion, leaking, and thus, offers a versatile vesicle delivery concept. There are a number 
of literature reports available, which prove the usefulness of oral proniosomal 
formulation for enhanced solubility and bioavailability for hydrophobic drug molecules 
[76].
Sayeed et al. prepared TQ-loaded proniosome based formulation for hepato-protective 
activity against methotrexate induced hepato-toxicity [77]. TQ-loaded proniosome 
prepared by thin-film hydration technique and characterized for particle size and 
entrapment efficiency. The size of vesicle found to be in nano-metric range with higher 
encapsulation efficiency. Findings from hepato-protective activity revealed that TQ-
loaded proniosomes significantly inhibited the elevated levels of liver enzymes, serum 
marker enzymes and improved histopathological abnormalities. This decrease in the 
level of serum marker enzymes suggested that TQ might be effective in the prevention 
of lipid peroxidation. 
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3.2.2.5 TQ-loaded liposomes
Liposomes are the most ideal drug-carrier system, composed of a phospholipid bilayer 
and aqueous core offering the encapsulation of both lipophilic and hydrophilic 
molecules. Their morphology is similar to that of cellular membranes and because of 
their ability to incorporate numerous constituents [78]. TQ-loaded liposomes mainly 
formulated to target different types of cancer cells and to treat bacterial infections, offer 
various advantages viz. improve dissolution profile and bioavailability [79].
Odeh et al. formulated TQ-loaded liposomes, evaluated its anticancer potential in T47D, 
and MCF-7, breast cancer cell lines, and periodontal ligament fibroblasts cells (PLF) 
[80]. The liposomes prepared by thin-film hydration technique and evaluated for particle 
size and entrapment efficiency. Results suggested that TQ-loaded liposomes were 
significantly effective in suppressing the proliferation in breast cancer cell-lines and 
showed very low toxicity on normal periodontal ligament fibroblast. Authors elucidated 
that liposomes led to the enhancement of bioavailability, permeability, EPR and 
sustained drug release of the TQ in the tumor cells as compared to the pure TQ. 
Recently, the same group co-encapsulated Docetaxel (DT) and TQ into PEGylated 
liposomes and valuated for cytotoxic effect against MCF7 breast cancer cell lines. 
DT/TQ laded PEGylated liposomes prepared by thin film dispersion method and 
characterized for encapsulation efficacy. Findings suggested that the combination of DT 
and TQ resulted in significant synergistic cytotoxicity compared to alone drugs. Authors 
explained that the cytotoxic effect induced by DT and TQ can be via blocking of the 
PI3K/Akt signaling pathway.  
In other study, Khan et al. formulated TQ-loaded liposomes for the treatment of Candida 
albicans infection against murine mouse model [81]. The anti-fungal activity of 
fluconazole, free TQ and TQ-loaded liposomes were measured through fungal load on 
the kidney tissue of treated mice. Findings confirmed that fluconazole and free TQ were 
also effective against Candida albicans but TQ-loaded liposomal formulation was 
significantly effective against both, fluconazole susceptible or resistance Candida 
albicans infection. Further, the authors concluded that TQ countered the anti-fungal 
activity via the immune escaping method. TQ was shown to induce ROS generation, 
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which managed to initiate the immune response of the host against Candida albicans. 
Similarly, Ahmad et al. evaluated TQ-loaded liposomes for radioprotection and 
enhanced blood circulation time employing the supercritical anti-solvent technique [82]. 
TQ-liposomal batch was evaluated for in vitro drug release, in vivo pharmacokinetic 
studies and in vivo radioprotection effect in rats employing γ-irradiation. Results 
confirmed that prepared TQ-liposomes were able to prolong circulation, whereas, 
results from in vivo study was translated into enhanced radioprotection for longer 
duration vis-à-vis pure TQ drug.
3.2.3 Non-particulate type systems
3.2.3.1 TQ-loaded SNEDDS
Self-nano emulsifying drug d livery systems (SNEDDS) is very popular owing to their 
numerous worthy aspects like microscopic globule size, easy to prepare, improved 
biocompatibility and higher stability [83]. SNEDDS primarily establish the blend of lipids, 
surfactants, co-surfactants, and/or co-solvents experiencing spontaneous 
emulsification. Pre-dissolving the drugs in the mixture of lipidic and emulsifying 
excipients omits the disintegration/dissolution steps, which are possible rate-limiting 
factors for oral absorption of poorly water-solubl  drugs [84].
Kalam et al. determined the hepatoprotective effect of prepared TQ-SNEDDS for 
augmentation of its hepatoprotective effects and oral bioavailability [85]. TQ-SNEDDS 
were formulated via construction of pseudo-ternary phase diagrams and characterized 
for thermodynamic stability, particle size and morphology. Results revealed the 3.87-
fold enhancement in oral bioavailability of TQ-SNEDDS in comparison with TQ 
suspension. In vivo hepatoprotective investigations exhibited significant 
hepatoprotective effects for optimized TQ-SNEDDS vis-à-vis TQ suspension. 
3.2.3.2 TQ-loaded nanoemulsions
 Nanoemulsions are nano-sized emulsions, manufactured for improving the delivery of 
active pharmaceutical materials. They are the thermodynamically stable and 
heterogeneous system where two immiscible liquids are mixed to form a single phase 
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by means of an emulsifying agent, i.e., surfactant and co-surfactant. This nanosized 
delivery system is proved to enhance the therapeutic efficacy of drug substance. 
Nanoemulsion delivery system increases the retention time of a drug in the body, so low 
amount of drug is required for the therapeutic action [86,87].
Tubesha et al. prepared TQ rich fraction NE for potential toxicity studies in Sprague 
Dawley rats as per the OECD guidelines [88]. At the end of the study, various 
parameters viz. body weight, hematological parameters, liver and kidney functioning 
test, and histopathology were studied. Findings suggested that TQ rich fraction NE was 
non-toxic by the oral route in Sprague-Dawley rats at a dose limit of 20 mL/kg. Results 
of various parameters of TQ rich fraction NE were compared to the control groups, 
suggested a wide range of safety for its therapeutic doses. Moreover, no hepatic toxicity 
was seen in histopathology evaluation. In other study, Dehghani et al. evaluated TQ-
loaded nanogel on human breast adenocarcinoma cell line (MCF-7) employing MTT 
and dye exclusion assay [89]. Findings suggested that the proliferation of MCF-7 cells 
was significantly inhibited by TQ-loaded nanogel formulation in comparison to pure TQ 
in a dose-dependent manner. Whereas, Ahmad et al. evaluated TQ-loaded 
mucoadhesive NE for the treatment of cerebral ischemia [90]. The prepared NE was 
also validated for pharmacokinetics, biodistribution and brain-targeting efficiency. The 
results suggested that intranasal to brain targeting revealed enhanced bioavailability of 
TQ in brain vis-à-vis intravenous administration. Improved neurobehavioural activity 
(locomotor and grip strength) was detected in middle cerebral artery occlusion induced 
cerebral ischemic rats after intranasal administration of NE vis-à-vis pure TQ. Similarly, 
Ismail et al. evaluated TQ rich fraction-loaded NE for treatment of Alzheimer’s disease 
(AD) in response to high fat/cholesterol diet (HFCD) induced rats [91]. Neuroprotective 
effect of TQ-rich fraction NE, TQ-NE and conventional emulsion were investigated in 
response to high fat/cholesterol diet (HFCD)-induced rats.  Amyloid-β (Aβ) generation; 
abnormal amyloid-β precursor protein (APP) processing, β-secretase 1 (BACE1), γ-
secretases of presenilin 1 (PSEN1) and presenilin 2 (PSEN2), Aβ degradation; insulin-
degrading enzyme (IDE), Aβ transportation; low density lipoprotein receptor-related 
protein 1 (LRP1) and receptor for advanced glycation end products (RAGE) were 
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measured in brain tissues. Findings suggested that TQ-NE reduced the accumulation of 
Aβ in brain that further modulate β- and γ-secretase enzyme activity, and the Aβ 
degradation and clearance from the brain tissues. 
 
El-Ashmawy et al. prepared doxorubicin (DOX) and TQ-loaded F2 gel nanofibers for 
enhanced antitumor activity and amelioration of doxorubicin-associated nephrotoxicity 
[92]. Antitumor potential was studied employing MCF-7 and HEPG2 cells lines and 
evaluated for apoptosis alongside with cellular proliferation. Findings suggested that 
nanofibre gel formulation showed a significant increase in apoptosis, caspase 3, and 
antioxidant enzymes; in comparision to, dramatic fall in cell viability, tumor volume, 
oxidative and nephrotoxicity markers, and NF-ϰB vis-à-vis free drug therapies.
4. Conclusions
An extensive pharmaceutical research on TQ was done in the past aiming to enhance 
the stability, improve oral bioavailability, permitting high therapeutic plasma drug 
concentrations, and minimize the toxicity associated with the drug. In this context, in the 
recent past years, various polymeric NCs, nanocapsules, nanoemulsions, liposomes, 
SLNs, NLCs, niosomes have witnessed the enhanced bioavailability and bioactivity of 
TQ. Despite of an enhanced efficacy over free TQ, TQ nano-formulations have not 
reached the clinical trials. Towards that aim, human trials should be conducted on TQ 
nano-formulations to establish the toxicological profiles of these formulations, and to 
approve their efficacy over free TQ. Only thus, it will be possible to evaluate the real 
contribution that nanotechnology embraces in the delivery of TQ. 
5. Expert opinion
Plant based bioactives have been used in the prevention and treatment of diseases 
throughout history due to their wide acceptability. Natural bioactives with antioxidant 
and anti-inflammatory properties have been used in the therapy of various chronic 
diseases. TQ is one such anti-oxidant molecule, which first identified in the essential oil 
of Nigella sativa L. black seed. During the past years, several studies have shown bright 
potential of TQ as an antioxidant, anti-inflammatory, and anti-cancer molecule in in vitro 
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and in vivo models. However, owing to its poor physico-chemical properties, its chances 
for FDA authorization and development as a potent medicine clinically is still delayed. 
TQ belongs to monoterpenes class of chemicals, and like other terpenoids is highly 
hydrophobic, poor aqueous solubility, high first-pass metabolism, and thus poor oral 
bioavailability.  To deal with poor biopharmaceutical properties associated with TQ, 
various novel drug delivery colloid-carrier systems encapsulating TQ attempted in the 
past, with enhanced bioavailability, and therapeutic efficacy. Novel carrier systems 
based on biocompatible polymers and lipids, protect the drug from external 
environment, and fr m the first pass metabolism. These drug delivery systems have the 
capability to improve the solubility and bioavailability of orally administered, poorly 
water-soluble and/or lipophilic drugs, while the carrier-based concept of drug delivery 
was employed. Nevertheless, these carrier systems could be impending in bringing forth 
this potential molecule to clinical reality.
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Figure legends
Figure 1: Molecular structure of TQ 
Figure 2: Schematic representation of the various biopharmaceutical, formulation, and 
patient-related hurdles associated with the delivery of TQ
Figure 3: Schematic illustration of absorption mechanisms employed by polymeric NCs 
for oral bioavailability enhancement of TQ presented by the GI tract. Drug transport via. 
epithelial cells as well as reversibly open tight junctions to allow for biologic transport 
through the paracellular pathway. M-cell mediated transport pathway is associated with 
the Peyer’s Patches, which further enhances lymphatic absorption of the drug and 
finally the drug absorption
Figure 4: Schematic illustration of absorption mechanisms employed by lipidic 
nanoparticles for oral bioavailability enhancement of drug. These encompass enhanced 
permeability across the enterocyte, absorption via. M cells of Peyer's patches, 
increased transcellular and paracellular transport. Transcellular routes further include 
transport of drug via. enterocytes viz. macro and pinocytosis, which further enhances 
the intestinal lymphatic transport and thus, the drug absorption
Figure 5: Various NC systems encapsulating TQ for management of various diseases
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Table 1: A tabular account of various TQ-loaded polymeric NC formulations 
Table 2: A tabular account of various TQ-loaded lipid NC formulations
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Figure 1: Molecular structure of TQ
Figure 2: Schematic representation of the various biopharmaceutical, formulation, and patient-
related hurdles associated with the delivery of TQ
Figure 3: Schematic illustration of absorption mechanisms employed by polymeric NCs for oral 
bioavailability enhancement of TQ presented by the GI tract. Drug transport via. epithelial cells as 
well as reversibly open tight junctions to allow for biologic transport through the paracellular 
pathway. M-cell mediated transport pathway is associated with the Peyer’s Patches, which further 
enhances lymphatic absorption of the drug and finally the drug absorption
Figure 4: Schematic illustration of absorption mechanisms employed by lipidic NCs for oral bioavailability 
enhancement of drug. These encompass enhanced permeability across the enterocyte, absorption via. M 
cells of Peyer's patches, increased transcellular and paracellular transport. Transcellular routes further 
include transport of drug via. enterocytes viz. macro and pinocytosis, which further enhances the intestinal 
lymphatic transport and thus, the drug absorption
Figure 5: Various NCs system encapsulating TQ for management of various diseases
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